Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Squamous Cell Carcinoma Head and Neck Cancer Recurrent Disease Patients must have pathologically confirmed recurrence (reappearance of previously cleared) squamous cell cancer primary in the upper aerodigestive tract .Patients may have experienced more than one recurrence as long as the first recurrence occurred ≥ 6 months following the end of the prior RT. 2. The recurrence must have defined bi or uni-dimensional measurements. 3. Recurrence must be confined to the head and neck above the clavicles (loco-regional recurrence). 4. The patient must not be a candidate for surgical resection. 5. Patients must be at least 6 months from completion of prior chemotherapy and radiation therapy. 6. Patients may have received prior chemotherapy as a component of their primary treatment, but not for recurrent disease. 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 8. Granulocytes ≥ 1500/mm3, platelets ≥ 100,000/mm3, serum bilirubin ≤ 1.5 mg/dl, creatinine < 1.5 mg/dl within 3 weeks prior to registration. 9. Liver Function Tests (LFTs) ≤ 2 x normal (serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic-pyruvic transaminase (SGPT)/Alkaline Phosphatase). If > 2 x normal, liver ultrasound or CT is required to metastases. If negative for metastases, patients are eligible. 10. Patients must sign a study-specific informed consent form prior to study entry  Distant metastases outside of the head and neck. 2. Primary disease in the nasopharynx or the salivary gland. 3. Other concurrent invasive malignancies. 4. Prior invasive malignancy unless disease free for at least two years (except prior in situ malignancies, e.g. cervix, breast, non-melanomatous skin cancer, etc. are permissible). 5. Intercurrent medical illnesses which would impair patient tolerance to therapy or limit survival. 6. Pre-existing grade ≥ 2 peripheral sensory neuropathy 7. Pregnant and nursing women are excluded because of the potential teratogenic effects and potential unknown effects on nursing newborns. 8. Prior history of sever hypersensitivity reaction to Docetaxol, Cetuximab or a drug with formulated with Polysorbate 80